Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Cytokinetics Inc

Healthcare US CYTK

79.17USD
0.39(0.49%)

Last update at 2026-06-22T20:00:00Z

Day Range

78.3680.80
LowHigh

52 Week Range

29.3170.98
LowHigh

Fundamentals

  • Previous Close 78.78
  • Market Cap8174.85M
  • Volume2885237
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-602.13299M
  • Revenue TTM88.04M
  • Revenue Per Share TTM0.73
  • Gross Profit TTM -327.98701M
  • Diluted EPS TTM-6.51

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -784.95500M -589.52600M -526.24400M -388.95500M -215.31400M
Minority interest - - - - -
Net income -784.95500M -589.52600M -526.24400M -402.55200M -242.37000M
Selling general administrative 284.27M 215.31M 173.61M 177.98M 96.80M
Selling and marketing expenses - - - - -
Gross profit 77.91M -320.93400M -322.59300M -146.22500M -89.51000M
Reconciled depreciation 10.12M 9.53M 7.21M 5.81M 2.28M
Ebit -784.95500M -503.01400M -468.57600M -324.20200M -186.31300M
Ebitda -775.26967M -493.48300M -456.68400M -312.86000M -185.98200M
Depreciation and amortization 9.69M 9.53M 11.89M 11.34M 0.33M
Non operating income net other - - - 11.34M 0.33M
Operating income -612.25800M -536.24800M -496.20500M -324.20200M -186.31300M
Other operating expenses 700.30M 554.72M 503.74M 418.79M 256.74M
Interest expense 103.87M 86.51M 57.67M 51.16M 29.33M
Tax provision - - - 0.00000M 0.00000M
Interest income 48.42M 51.53M 25.96M 11.34M 0.33M
Net interest income -55.44800M -34.97800M -30.91100M -39.81400M -29.00100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 11.72M 13.60M 27.06M
Total revenue 88.04M 18.47M 7.53M 94.59M 70.43M
Total operating expenses 690.17M 215.31M 173.61M 177.98M 96.80M
Cost of revenue 10.12M 339.41M 330.12M 240.81M 159.94M
Total other income expense net -172.69700M -53.27800M -30.03900M -64.75300M -29.00100M
Discontinued operations - - - - -
Net income from continuing ops -784.95500M -589.52600M -526.72800M -332.27400M -202.42200M
Net income applicable to common shares - - - -388.95500M -215.31400M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1424.54M 1401.67M 824.32M 1014.77M 841.32M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 34.75M 15.28M 11.57M 12.61M 64.03M
Total liab 2084.16M 1537.05M 1210.64M 1122.67M 597.46M
Total stockholder equity -659.62500M -135.37200M -386.32300M -107.90000M 243.86M
Deferred long term liab - - - - 87.00M
Other current liab 36.55M 76.44M 53.20M 46.18M 1.54M
Common stock 0.12M 0.12M 0.10M 0.09M 0.08M
Capital stock 0.12M 0.12M 0.10M 0.09M 0.08M
Retained earnings -3486.71900M -2701.76400M -2112.23800M -1585.99400M -1207.62000M
Other liab - - - 300.54M 270.53M
Good will - - - - -
Other assets - - - 9.69M 7.19M
Cash 882.22M 94.86M 113.40M 65.58M 112.67M
Cash and equivalents - - - - -
Total current liabilities 202.45M 179.67M 102.68M 84.62M 71.86M
Current deferred revenue - 52.37M - - 34.37M
Net debt 402.02M 693.82M 642.37M 683.76M 157.26M
Short term debt 60.29M 30.50M 27.97M 12.83M 14.86M
Short long term debt 41.18M 11.52M 10.08M - -
Short long term debt total 1284.24M 788.68M 755.77M 749.34M 269.93M
Other stockholder equity 2826.34M 2563.88M 1725.82M 1481.59M 1452.27M
Property plant equipment - - - 80.45M 73.27M
Total current assets 916.98M 1107.94M 628.05M 795.19M 535.67M
Long term investments 335.05M 145.06M 40.53M 46.71M 152.05M
Net tangible assets - - - -107.90000M 243.86M
Short term investments 759.70M 981.16M 501.80M 717.00M 358.97M
Net receivables 17.76M 16.65M 1.28M 0.15M 51.82M
Long term debt 1115.98M 645.60M 607.37M 63.81M 47.37M
Inventory - - - -0.14700M -51.81900M
Accounts payable 105.61M 20.37M 21.51M 25.61M 21.09M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.63M 2.40M -0.01000M -3.59000M -0.86900M
Additional paid in capital - - - - -
Common stock total equity - - - 0.09M 0.08M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -1585.99400M -1207.62000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 17.34M 7.71M 8.00M 9.69M 7.19M
Deferred long term asset charges - - - - -
Non current assets total 507.56M 293.73M 196.26M 219.59M 305.65M
Capital lease obligations 127.08M 131.56M 138.32M 139.72M 127.09M
Long term debt total - - - 63.81M 47.37M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 41.47M -553.09700M 349.91M -250.79900M -98.90500M
Change to liabilities - - - -75.69000M 19.76M
Total cashflows from investing activities 16.67M -553.09700M - -262.13400M -147.77700M
Net borrowings 315.95M -9.61800M - 473.53M 334.66M
Total cash from financing activities 524.46M 930.61M 221.32M 516.17M 319.98M
Change to operating activities - - - 1.10M 54.80M
Net income -784.95500M -589.52600M -526.24400M -388.95500M -215.31400M
Change in cash 30.40M -18.16700M 47.82M -45.48400M 29.68M
Begin period cash flow 95.23M 113.40M 65.58M 112.67M 82.98M
End period cash flow 125.63M 95.23M 113.40M 67.18M 112.67M
Total cash from operating activities -510.00900M -395.89000M -414.33300M -299.51600M -142.52200M
Issuance of capital stock 0.00000M 706.84M 1.31M 15.14M 312.05M
Depreciation 10.12M 9.53M 11.89M 5.81M 2.28M
Other cashflows from investing activities -5.00000M - - - -
Dividends paid - - 18.46M - -
Change to inventory - - - - -
Change to account receivables -1.11400M -15.36700M -1.13600M 56.67M -47.39900M
Sale purchase of stock - 53.02M -10.51700M 17.54M -4.44900M
Other cashflows from financing activities -2.46800M 233.38M 232.69M 670.00M 12.38M
Change to netincome - - - 78.60M 33.96M
Capital expenditures 24.81M 3.91M 1.42M 11.34M 48.87M
Change receivables - - - 56.67M -47.39900M
Cash flows other operating - - - 24.05M 64.19M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -45.48400M 29.68M
Change in working capital -35.62800M 35.66M 3.09M -24.70400M 8.46M
Stock based compensation 112.29M 97.84M 72.06M 47.85M 26.83M
Other non cash items 300.45M 50.60M 20.25M 60.48M 32.38M
Free cash flow -534.81600M -399.79600M -415.74900M -310.85100M -191.39400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CYTK
Cytokinetics Inc		 0.39 0.49% 79.17 - 117.65 92.85 60.31 97.90 -15.824
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Cytokinetics Inc

350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Mr. Robert I. Blum CEO, Pres & Director 1964
Mr. Ching W. Jaw Sr. VP & CFO 1963
Dr. Fady Ibraham Malik FACC, M.D., Ph.D. Exec. VP of R&D 1964
Mr. Andrew M. Callos Exec. VP & Chief Commercial Officer 1956
Dr. James A. Spudich Ph.D. Co-Founder & Member of Scientific Advisory Board 1942
Mr. Jeff Lotz VP of Sales & Operations NA
Mr. Robert C. Wong VP & Chief Accounting Officer 1968
Ms. Joanna Siegall Associate Director of Corp. Communications & Investor Relations NA
Ms. Kari K. Loeser J.D. VP & Chief Compliance Officer NA
Mr. Scott R. Jordan Sr. VP of Global Marketing & Commercial Strategy NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.